Anixa Biosciences Inc. has announced the completion of enrollment in its Phase 1 clinical trial for a novel breast cancer vaccine, developed in partnership with Cleveland Clinic. The trial, which includes 35 women across three distinct patient cohorts, is fully funded by a grant from the U.S. Department of Defense. The vaccine aims to stimulate the immune system to target breast cancer before it can recur or develop. Encouraged by preliminary results showing a high level of immune response, Anixa is planning for Phase 2 trials and will submit trial data for presentation at a major scientific meeting.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。